Stock Events

Stock Events

ARS Pharmaceuticals 

$8.19
0
+$0+0% Today

Statistics

Day High
8.2
Day Low
7.8
52W High
-
52W Low
-
Volume
356
Avg. Volume
-
Mkt Cap
809.57M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2025
Q4 2025
Next
-0.52
-0.48
-0.45
-0.41
Expected EPS
-0.4858
Actual EPS
N/A

Financials

8.97%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
178.3MRevenue
16MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SPRY.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical is a global leader in generic and specialty medicines, including treatments for respiratory conditions, making it a direct competitor in the pharmaceutical market.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is involved in the development of respiratory treatments among its diverse pharmaceutical portfolio, competing in the same therapeutic area as ARS.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a significant presence in the respiratory treatment market, including asthma and COPD, directly competing with ARS Pharmaceuticals.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. offers a wide range of health solutions, including respiratory disease treatments, making it a competitor in the pharmaceutical industry.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad portfolio that includes respiratory drugs, competing with ARS Pharmaceuticals in the development and marketing of these treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, with its extensive research and development in respiratory conditions, competes in the same market as ARS Pharmaceuticals.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for its innovative biopharmaceuticals, competes in the development of treatments for conditions that ARS Pharmaceuticals targets.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is focused on serious diseases, including cystic fibrosis, a respiratory condition, making it a competitor.
Sanofi
SNY
Mkt Cap124.45B
Sanofi focuses on global healthcare and provides treatments for respiratory conditions, competing with ARS Pharmaceuticals in the same therapeutic area.

About

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Show more...
CEO
ISIN
US82835W1080

Listings

XNAS
US
SPRY
BOATS
BOATS
SPRY.BOATS

0 Comments

Share your thoughts

FAQ

What is ARS Pharmaceuticals stock price today?▼
The current price of SPRY.BOATS is $8.19 USD — it has increased by +0% in the past 24 hours. Watch ARS Pharmaceuticals stock price performance more closely on the chart.
What is ARS Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ARS Pharmaceuticals stocks are traded under the ticker SPRY.BOATS.
What is ARS Pharmaceuticals market cap?▼
Today ARS Pharmaceuticals has the market capitalization of 809.57M
When is the next ARS Pharmaceuticals earnings date?▼
ARS Pharmaceuticals is going to release the next earnings report on May 19, 2026.
What were ARS Pharmaceuticals earnings last quarter?▼
SPRY.BOATS earnings for the last quarter are -0.41 USD per share, whereas the estimation was -0.43 USD resulting in a +4.62% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ARS Pharmaceuticals revenue for the last year?▼
ARS Pharmaceuticals revenue for the last year amounts to 178.3M USD.
What is ARS Pharmaceuticals net income for the last year?▼
SPRY.BOATS net income for the last year is 16M USD.
When did ARS Pharmaceuticals complete a stock split?▼
ARS Pharmaceuticals has not had any recent stock splits.